EASL Congress webpage publishes survodutide fatty liver data ahead of schedule by accident
![Photo: Boehringer Ingelheim / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article11759217.ece/ALTERNATES/schema-16_9/doc77zhwlo7111r11qhjv.jpg)
An abstract of data from a Phase II study of survodutide in fatty liver disease, or MASH, was inadvertently and briefly published on the European Association of the Study of the Liver Congress (EASL) website.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.